Quipt Home Medical Corp. (QIPT Q4 FY2023 earnings call

• Quipt has expanded to 125 locations across 26 states with over 287,000 active patients, strengthening its coast-to-coast reach.
• Fiscal 2023 saw strong demand trends across all product categories, favorable regulatory landscape, and successful integration of acquisitions.
• The sleep segment experienced no impact from GLP 1 diabetes and weight loss medications, with continued strong demand.
• The company leverages technology in e-prescribing and automated resupply to improve operational performance and drive organic growth.
• Focus on growing the continuum of care, cross-selling product categories, and operating in a favorable regulatory environment to increase organic growth.

Quipt Home Medical is a diversified healthcare services company focused on clinical respiratory care, with over 80% of its product mix being respiratory in nature. For fiscal 2023, the company recorded record revenue of $221.7 million, representing a 58.5% year-over-year growth. Adjusted EBITDA was $50.6 million, a 73.5% year-over-year growth, with a margin of 22.8%. In fiscal Q4 2023, revenue was $62.5 million, a 56% year-over-year increase, and adjusted EBITDA was $14.7 million with a margin of 23.5%. Recurring revenue as of fiscal 2023 exceeded 83% of total revenue.

• Quipt expects steady and continuous organic growth in fiscal 2024 with an objective of 8% to 10% on an annualized basis.
• Fiscal Q1 2024 is showing momentum with continued organic growth and margin expansion.
• The company anticipates improving net cash flow from operations in fiscal 2024, building on the base case from fiscal 2023.

• Regulatory risks such as the potential return of competitive bidding, though likelihood is decreasing.
• Labor strikes or Medicare changes could indirectly impact the business, but no major direct impacts observed so far.
• Interest rate component to be carefully monitored when evaluating acquisitions.

Q: Doug Cooper asked about the resupply program, average reorder rate per patient, and revenue per reorder.

A: Greg Crawford responded that patients order about three times a year, average revenue per reorder is just over $200, totaling just over $600 per patient.

Q: Ty Collin asked about margin outlook for 2024 and low hanging fruits for improvement.

A: Greg Crawford stated that margins are expected to be within a good plus and minus 5% range, with low hanging fruits including leveraging scale and operational efficiencies.

Q: Richard Close asked about revenue estimate beat, bad debt, and acquisition pipeline.

A: Hardik Mehta mentioned the company beat revenue estimates, bad debt is a work in progress, and there are opportunities for acquisitions with careful consideration of interest rates and cash flow.

Q: Bill Sutherland asked about sales force growth and insurance contracting.

A: Greg Crawford said the sales force is over 90, with growth from new hires, and insurance contracting is ongoing with large payers like Anthem and Cigna.

Q: Julian Hung asked about labor challenges and Medicare impact.

A: Greg Crawford stated no direct impact from labor strikes, and Medicare changes are not expected to significantly impact revenue, though bad debt could be affected.